750
Participants
Start Date
June 2, 2021
Primary Completion Date
December 15, 2024
Study Completion Date
December 15, 2024
Xultophy® (insulin degludec/liraglutide)
"Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study."
Dongguk University Ilsan Hospital, Goyang
Uijeongbu Eulji university Hospital, Uijeongbu-si
Seoul National University Bundang Hospital, Gyeonggi-do
Hyewon Medical Foundation Sejong General Hospital, Gyeonggi-do
The Catholic University of Korea. St. Vincent's Hospital, Suwon-si, Gyeonggi-do
Ajou University Hospital, Gyeonggi-do
Dongtan Jeil Women's Hospital, Hwasung-si
Inha University Hospital, Incheon
Soonchunhyang University Hospital, Cheonan
Daejeon Endo Internal Medicine Clinic, Daejeon
Daejeon Endo Internal Medicine Clinic, Daejeon
Keimyung University Dongsan Hospital, Daegu
Keimyung University Dongsan Medical Center, Daegu
Ulsan Hospital, Ulsan
Isam Hospital, Busan
Inje University Busan Paik Hospital, Busan
Kosin University Gospel Hospital, Busan
Gyeongsang National University Hospital, Gyeongsangnam-do
Sahm Yook Medical Center, Seoul
Eulji University Hospital_Daejeon, Daejeon
Chungbuk National University Hospital, Daejeon
ChonBuk Nataional University Hospital, Jeonju
Hanil General Hospital, Seoul
Nowon Eulji Medical Center, Eulji University, Seoul
Yonsei Leehyunchul Internal Medicine, Seoul
Inje University Seoul Paik Hospital, Seoul
Gangdong Kyung Hee University Hospital, Seoul
Seoul Saint Mary's Hospital, Seoul
KangNam Sacred Heart Hospital, Seoul
St. Mary's Hospital, The Catholic University of Korea, Seoul
Ulsan University Hospital, Ulsan
Lead Sponsor
Novo Nordisk A/S
INDUSTRY